Literature DB >> 7580003

Comparison between depot leuprorelin and daily buserelin in IVF.

E Porcu1, M Filicori, L Dal Prato, R Fabbri, R Seracchioli, C Colombi, C Flamigni.   

Abstract

OBJECTIVES: To compare the effects of depot and daily forms of GnRH analogs in IVF programs.
METHODS: One hundred seventeen patients undergoing IVF, with no severe male factor, were randomized between two treatment groups. Pituitary desensitization was obtained in group 1 (60 patients) with a single IM injection of leuprorelin (3.75 mg), and in group 2 (57 patients) with buserelin (0.3 mg SC twice daily). In a subgroup of 10 patients (5 for the depot form and 5 for the daily form) several GnRH tests were performed to investigate pituitary desensitization.
RESULTS: No differences were found in the time to reach desensitization. Resumption of pituitary activity occurred in 7 days with the daily form and in about 2 months with the depot form. No significant differences were found in the stimulation pattern, oocyte quality, percentage of fertilization. The pregnancy rate per transfer was slightly, but not significantly, better in the depot group (29.4% vs 25.9%). Implantation rate (11.9% vs 12.3%) and the percentage of miscarriages (26.6% vs 28.5%) were similar.
CONCLUSION: Depot and daily forms of GnRH analogs are equally effective in superovulation induction for IVF. Considering improved patient compliance and preference, depot forms are advantageous.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7580003     DOI: 10.1007/BF02214123

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  15 in total

1.  Pregnancy during long-term gonadotropin-releasing hormone agonist therapy associated with clinical pseudomenopause.

Authors:  J Har-Toov; S H Brenner; A Jaffa; H Yavetz; M R Peyser; J B Lessing
Journal:  Fertil Steril       Date:  1993-02       Impact factor: 7.329

2.  Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results.

Authors:  E Porcu; L Dal Prato; R Seracchioli; R Fabbri; M Longhi; C Flamigni
Journal:  Fertil Steril       Date:  1994-07       Impact factor: 7.329

3.  Inhibition of human granulosa cell progesterone secretion by a gonadotropin-releasing hormone agonist.

Authors:  R W Tureck; L Mastroianni; L Blasco; J F Strauss
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

4.  Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon.

Authors:  I S Kang; T J Kuehl; T M Siler-Khodr
Journal:  Fertil Steril       Date:  1989-11       Impact factor: 7.329

5.  Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women.

Authors:  M Filicori; C Flamigni; G Cognigni; P Dellai; R Arnone; A Falbo; M Capelli
Journal:  J Clin Endocrinol Metab       Date:  1993-07       Impact factor: 5.958

6.  Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor.

Authors:  R F Casper; S S Yen
Journal:  Science       Date:  1979-07-27       Impact factor: 47.728

7.  Effect of a luteinizing hormone-releasing hormone agonist (Buserelin) on steroidogenesis of cultured human preovulatory granulosa cells.

Authors:  J Parinaud; A Beaur; E Bourreau; G Vieitez; G Pontonnier
Journal:  Fertil Steril       Date:  1988-10       Impact factor: 7.329

8.  The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT.

Authors:  J Smitz; P Devroey; M Camus; J Deschacht; I Khan; C Staessen; L Van Waesberghe; A Wisanto; A C Van Steirteghem
Journal:  Hum Reprod       Date:  1988-07       Impact factor: 6.918

9.  Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone.

Authors:  A Herman; R Ron-El; A Golan; H Nachum; Y Soffer; E Caspi
Journal:  Hum Reprod       Date:  1992-04       Impact factor: 6.918

10.  The comparison of two gonadotropin-releasing hormone agonists in an in vitro fertilization program.

Authors:  J Balasch; I C Jové; V Moreno; S Civico; B Puerto; J A Vanrell
Journal:  Fertil Steril       Date:  1992-11       Impact factor: 7.329

View more
  2 in total

1.  Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response.

Authors:  Selmo Geber; Liana Sales; Marcos A C Sampaio
Journal:  J Assist Reprod Genet       Date:  2002-07       Impact factor: 3.412

Review 2.  Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles.

Authors:  Luiz Eduardo T Albuquerque; Leopoldo O Tso; Humberto Saconato; Maria Cecília R M Albuquerque; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.